Brian J Miller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/27043/publications.pdf

Version: 2024-02-01

93 papers 6,857 citations

33 h-index 81 g-index

93 all docs 93 docs citations 93 times ranked 8740 citing authors

#	Article	IF	CITATIONS
1	Insomnia and suicide as reported adverse effects of second-generation antipsychotics and mood stabilizers. Journal of Clinical Sleep Medicine, 2022, 18, 517-522.	2.6	10
2	Insomnia and triglycerides in schizophrenia. Schizophrenia Research, 2022, 239, 42-43.	2.0	2
3	Epigenetics and first-episode psychosis: A systematic review. Psychiatry Research, 2022, 307, 114325.	3. 3	4
4	Development of Autonomic Nervous System Assays as Point-of-Care Tests to Supplement Clinical Judgment in Risk Assessment for Suicidal Behavior: A Review. Current Psychiatry Reports, 2022, 24, 11-21.	4.5	6
5	Inflammation, hippocampal volume, and cognition in schizophrenia: results from the Northern Finland Birth Cohort 1966. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 609-622.	3.2	19
6	Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: A review of the literature and recommendations for the COVID-19 pandemic. Brain, Behavior, and Immunity, 2021, 91, 756-770.	4.1	38
7	Medication management of antipsychotic treatment in schizophrenia—A narrative review. Human Psychopharmacology, 2021, 36, e2765.	1.5	2
8	The pupillary light reflex as a point-of-care test for suicide risk: Preliminary results. Psychiatry Research, 2021, 295, 113582.	3.3	6
9	Insomnia, Suicidal Ideation, and Suicide Attempts in the Clinical Antipsychotic Trials of Intervention Effectiveness. Journal of Clinical Psychiatry, 2021, 82, .	2.2	12
10	Immune-inflammatory markers and psychosis risk: A systematic review and meta-analysis. Psychoneuroendocrinology, 2021, 127, 105200.	2.7	43
11	Monitoring for myocarditis during treatment initiation with clozapine. Acta Psychiatrica Scandinavica, 2021, 144, 194-200.	4.5	11
12	Pupillary light reflex markers of suicide risk in a trans-diagnostic sample. Schizophrenia Research, 2021, 235, 1-2.	2.0	5
13	Insomnia and inflammation in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Psychiatry Research, 2021, 305, 114195.	3.3	3
14	Insomnia, suicidal ideation, and psychopathology in Chinese patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110202.	4.8	18
15	The interaction of lipids and inflammatory markers predict negative symptom severity in patients with schizophrenia. NPJ Schizophrenia, 2021, 7, 50.	3.6	6
16	Meta-analysis of cytokine and C-reactive protein levels in high-risk psychosis. Schizophrenia Research, 2020, 226, 5-12.	2.0	40
17	Metaâ€analysis of total and differential white blood cell counts in schizophrenia. Acta Psychiatrica Scandinavica, 2020, 142, 18-26.	4.5	62
18	Meta-analysis of comorbid diabetes and family history of diabetes in non-affective psychosis. Schizophrenia Research, 2020, 216, 41-47.	2.0	13

#	Article	IF	CITATIONS
19	Reply to the Letter to the Editor: Reduced neuropsychiatric events as "beneficial reactions―to drugs: Seek associations with caution. Brain, Behavior, and Immunity, 2020, 84, 277.	4.1	1
20	Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Comprehensive Psychiatry, 2020, 102, 152195.	3.1	5
21	Psychosis as an adverse effect of antibiotics. Brain, Behavior, & Immunity - Health, 2020, 9, 100148.	2.5	19
22	Longitudinal study of inflammatory markers and psychopathology in schizophrenia. Schizophrenia Research, 2020, 224, 58-66.	2.0	22
23	Screening for plagiarism in psychiatric research: Similarity scores are not all the same. Journal of Psychiatric Research, 2020, 131, 31-32.	3.1	1
24	Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder. Focus (American) Tj ETQq0 0 0 rgBT	/Overlock 0.8	10 Tf 50 542
25	Acutely ill psychiatric inpatients and antimicrobial exposure. , 2020, 32, 229-238.		4
26	Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophrenia Research, 2019, 209, 193-197.	2.0	16
27	Psychosis as an adverse effect of monoclonal antibody immunotherapy. Brain, Behavior, and Immunity, 2019, 81, 646-649.	4.1	13
28	O10.5. META-ANALYSIS OF CYTOKINE LEVELS AND PSYCHOPATHOLOGY IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S191-S192.	4.3	5
29	Meta-analysis of blood cortisol levels in individuals with first-episode psychosis. Psychoneuroendocrinology, 2019, 104, 269-275.	2.7	32
30	Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study. Schizophrenia Research, 2019, 208, 44-48.	2.0	5
31	Rates of hepatitis B and C in patients with schizophrenia: A meta-analysis. General Hospital Psychiatry, 2019, 61, 41-46.	2.4	20
32	Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology. Biomarkers in Neuropsychiatry, 2019, 1, 100006.	1.0	37
33	Total and Differential White Blood Cell Counts, Cocaine, and Marijuana Use in Patients With Schizophrenia. Journal of Nervous and Mental Disease, 2019, 207, 633-636.	1.0	5
34	Insomnia and suicidal ideation in nonaffective psychosis. Sleep, 2019, 42, .	1,1	32
35	Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine. Schizophrenia Research, 2019, 206, 21-26.	2.0	21
36	Urinary tract infection, inflammation, and cognition in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Annals of Clinical Psychiatry, 2019, 31, 242-248.	0.6	0

#	Article	IF	CITATIONS
37	Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. Molecular Neurobiology, 2018, 55, 4195-4206.	4.0	279
38	TNF- \hat{l}_{\pm} and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophrenia Research, 2018, 199, 281-284.	2.0	93
39	Total and differential white blood cell counts and hemodynamic parameters in first-episode psychosis. Psychiatry Research, 2018, 260, 307-312.	3.3	36
40	Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression. Schizophrenia Bulletin, 2018, 44, 75-83.	4.3	262
41	Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophrenia Research, 2018, 195, 275-282.	2.0	24
42	F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE. Schizophrenia Bulletin, 2018, 44, S242-S243.	4.3	0
43	2329 Associations between inflammatory markers and negative symptoms in individuals with schizophrenia: Converging evidence. Journal of Clinical and Translational Science, 2018, 2, 4-4.	0.6	0
44	Meta-Analysis of Cytokine and Chemokine Genes in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2018, 12, 121-129B.	1.4	32
45	Rheumatoid Arthritis Drugs for Schizophrenia?. Psychiatric Annals, 2018, 48, 232-236.	0.1	0
46	Monoclonal antibody immunotherapy in psychiatric disorders. Lancet Psychiatry, the, 2017, 4, 13-15.	7.4	16
47	Recurrent urinary tract infections in psychotic mood disorders. Schizophrenia Research, 2017, 184, 137-138.	2.0	1
48	Personalized medicine for schizophrenia. NPJ Schizophrenia, 2017, 3, 2.	3.6	17
49	Urinary tract infections in children and adolescents with acute psychosis. Schizophrenia Research, 2017, 183, 36-40.	2.0	16
50	Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-na \tilde{A} -ve patients with nonaffective psychosis. Schizophrenia Research, 2017, 179, 57-63.	2.0	85
51	Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions. Neuropsychopharmacology, 2017, 42, 299-317.	5.4	132
52	Recurrent urinary tract infections in children and adolescents with acute psychosis. Schizophrenia Research, 2017, 184, 103-104.	2.0	2
53	Electronic cigarette use in patients with schizophrenia: Prevalence and attitudes. Annals of Clinical Psychiatry, 2017, 29, 4-10.	0.6	27
54	Parental type 2 diabetes in patients with non-affective psychosis. Schizophrenia Research, 2016, 175, 223-225.	2.0	12

#	Article	IF	CITATIONS
55	Prolactin concentrations in antipsychotic-na \tilde{A} -ve patients with schizophrenia and related disorders: A meta-analysis. Schizophrenia Research, 2016, 174, 156-160.	2.0	64
56	The Case for Adjunctive Monoclonal Antibody Immunotherapy in Schizophrenia. Psychiatric Clinics of North America, 2016, 39, 187-198.	1.3	32
57	Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis. Psychoneuroendocrinology, 2016, 63, 144-154.	2.7	58
58	An Open-Label, Pilot Trial of Adjunctive Tocilizumab in Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, 275-276.	2.2	65
59	Inflammationâ€induced activation of the indoleamine 2,3â€dioxygenase pathway: Relevance to cancerâ€related fatigue. Cancer, 2015, 121, 2129-2136.	4.1	68
60	Beyond Urinary Tract Infections (UTIs) and Delirium. Journal of Psychiatric Practice, 2015, 21, 402-411.	0.7	38
61	Recurrent urinary tract infections in acute psychosis. Schizophrenia Research, 2015, 164, 275-276.	2.0	12
62	Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophrenia Research, 2015, 169, 30-35.	2.0	27
63	How connected are people with schizophrenia? Cell phone, computer, email, and social media use. Psychiatry Research, 2015, 225, 458-463.	3.3	103
64	Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses. Brain, Behavior, and Immunity, 2015, 45, 28-35.	4.1	30
65	Meta-Analysis of Anti- <i>Toxoplasma gondii</i> lgM Antibodies in Acute Psychosis. Schizophrenia Bulletin, 2015, 41, 989-998.	4.3	53
66	Schizophrenia Research. Psychiatric Clinics of North America, 2015, 38, 373-377.	1.3	4
67	Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients. Biological Psychiatry, 2015, 78, 28-37.	1.3	272
68	The Antipsychotic Effects of ECT. Journal of ECT, 2014, 30, 125-131.	0.6	37
69	Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2014, 8, 73-79.	1.4	39
70	A dose reduction/discontinuation strategy improves long-term recovery in people with remitted first-episode psychosis compared to maintenance therapy. Evidence-Based Mental Health, 2014, 17, 10-10.	4.5	0
71	Cysteamine, a pro-BDNF drug, as an adjunctive treatment for schizophrenia. Schizophrenia Research, 2014, 158, 268-269.	2.0	3
72	US Medical Licensing Exam Scores and Performance on the Psychiatry Resident In-Training Examination. Academic Psychiatry, 2014, 38, 627-631.	0.9	10

#	Article	IF	CITATIONS
73	C-Reactive Protein Levels in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2014, 7, 223-230.	1.4	202
74	Urinary Tract Infections in Acute Psychosis. Journal of Clinical Psychiatry, 2014, 75, 379-385.	2.2	31
75	A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophrenia Research, 2013, 150, 245-251.	2.0	93
76	Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects. Biological Psychiatry, 2013, 73, 993-999.	1.3	180
77	Differential white blood cell counts may predict urinary tract infection in acute non-affective psychosis. Schizophrenia Research, 2013, 147, 400-401.	2.0	8
78	Meta-Analysis of Oxidative Stress in Schizophrenia. Biological Psychiatry, 2013, 74, 400-409.	1.3	408
79	Inflammation and Schizophrenia. Schizophrenia Bulletin, 2013, 39, 1174-1179.	4.3	266
80	Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain, Behavior, and Immunity, 2013, 31, 82-89.	4.1	48
81	Prenatal inflammation and neurodevelopment in schizophrenia: A review of human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 42, 92-100.	4.8	101
82	A Prevalence Study of Urinary Tract Infections in Acute Relapse of Schizophrenia. Journal of Clinical Psychiatry, 2013, 74, 271-277.	2.2	50
83	Is Abnormal Glucose Tolerance in Antipsychotic-Naive Patients With Nonaffective Psychosis Confounded by Poor Health Habits?. Schizophrenia Bulletin, 2012, 38, 280-284.	4.3	69
84	Is Relapse in Schizophrenia an Immune-Mediated Effect?. Focus (American Psychiatric Publishing), 2012, 10, 115-123.	0.8	6
85	Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects. Biological Psychiatry, 2011, 70, 663-671.	1.3	1,448
86	Meta-analysis of Paternal Age and Schizophrenia Risk in Male Versus Female Offspring. Schizophrenia Bulletin, 2011, 37, 1039-1047.	4.3	167
87	Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review. Clinical Psychopharmacology and Neuroscience, 2011, 9, 45-53.	2.0	25
88	Advanced Paternal Age, Mortality, and Suicide in the General Population. Journal of Nervous and Mental Disease, 2010, 198, 404-411.	1.0	15
89	Paternal age and mortality in nonaffective psychosis. Schizophrenia Research, 2010, 121, 218-226.	2.0	8
90	Psychiatric Comorbidities and Schizophrenia. Schizophrenia Bulletin, 2009, 35, 383-402.	4. 3	867

BRIAN J MILLER

#	Article	IF	CITATIONS
91	Parental history of Type 2 diabetes in patients with nonaffective psychosis. Schizophrenia Research, 2008, 98, 302-306.	2.0	74
92	A Review of Second-Generation Antipsychotic Discontinuation in First-Episode Psychosis. Journal of Psychiatric Practice, 2008, 14, 289-300.	0.7	38
93	Mortality and Medical Comorbidity Among Patients With Serious Mental Illness. Psychiatric Services, 2006, 57, 1482-1487.	2.0	235